BackTheravance Biopharma Overview

Theravance Biopharma Current Cash

Theravance Biopharma's current cash is $290M.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$288.10M
160.46% YoYΔ $177.49M vs prior year quarter

Peer average

Loading

Theravance Biopharma Current Cash History

Loading

Theravance Biopharma vs. peers: Current Cash Comparison

Loading

Theravance Biopharma Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Theravance Biopharma (TBPH) FAQ

As of the most recent data (March 2026), TBPH shows a current cash of $290M. That compares with $110M in the prior-year period — up 160.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, TBPH's current cash is now $290M (was $110M) — a 160.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Theravance Biopharma is outperforming or lagging.

Tracking TBPH's current cash over time shows whether Theravance Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $290M That compares with $110M in the prior-year period — up 160.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has Theravance Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $290M) with ownership activity and broader fundamentals.

Theravance Biopharma's current cash is $290M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.